Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has earned a consensus recommendation of “Buy” from the thirteen research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $54.7273.

A number of equities analysts have recently commented on XENE shares. Royal Bank Of Canada raised their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Wells Fargo & Company upped their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th.

Insider Buying and Selling

In other news, CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at $266,580. The trade was a 86.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 65,302 shares of company stock valued at $2,924,128. 4.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several large investors have recently added to or reduced their stakes in XENE. Cinctive Capital Management LP raised its holdings in Xenon Pharmaceuticals by 1.1% in the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after purchasing an additional 263 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Xenon Pharmaceuticals by 1.8% in the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 334 shares during the last quarter. State of Wyoming boosted its holdings in Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 350 shares during the last quarter. Quarry LP grew its stake in shares of Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares during the period. Finally, Altfest L J & Co. Inc. raised its position in Xenon Pharmaceuticals by 6.5% in the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 501 shares during the period. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Up 1.3%

XENE opened at $43.08 on Friday. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.60. The company has a market cap of $3.33 billion, a PE ratio of -11.07 and a beta of 0.96. The company has a 50 day moving average of $42.46 and a 200 day moving average of $40.59.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.